ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient …
WebWhat is ENHERTU? ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
Web4 days ago · Enhertu expected to become new standard for treating metastatic breast cancer with low HER2 protein levels. Trastuzumab was developed in the 1990s specifically to treat breast cancer. That’s because studies at the time had shown that tumors in about 20% of people with breast cancer had an overabundance of HER2 on their surfaces, …
Enhertu demonstrated statistically significant and clinically ...
WebApr 29, 2024 · Enhertu (5.4 mg/kg) is approved in more than 35 countries for the treatment of adult patients with unresectable or metastatic NSCLC whose tumours have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 …
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
WebUPDATE: On August 5, 2022, the Food and Drug Administration (FDA) approved trastuzumab deruxtecan (Enhertu) for the treatment of HER2-low breast cancers that can’t be removed surgically, or that have spread (metastasized) elsewhere in the body. Before receiving trastuzumab deruxtecan, people must have either.
ENHERTU® Demonstrated Statistically Significant and Clinically ...
WebApr 29, 2024 · ENHERTU U.S. Important Safety Information. Indications ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: In the …
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WebOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show. Trastuzumab deruxtecan was also better at shrinking tumors, the DESTINY-Breast03 trial found.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Patient Site
WebWhat is ENHERTU? ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy: - for metastatic disease, or.
Enhertu: Uses, Dosage, Side Effects, Warnings - Drugs.com
WebApr 9, 2024 · Enhertu is used to treat certain types of breast cancer, stomach cancer, and non-small cell lung cancer that have specific HER2 gene mutations. Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate.
FDA approves new treatment option for patients with HER2 …
WebEnhertu is a human epidermal growth factor receptor 2 (HER2)-directed antibody and topoisomerase inhibitor conjugate, meaning that the drug targets the changes in HER2 that help the cancer grow,...
Enhertu | European Medicines Agency
WebDec 11, 2020 · Overview. Enhertu is a medicine used for treating adults with: HER2-positive breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery. HER2-positive means that the cancer cells produce a protein called HER2 in large quantities on their surface, which makes the tumour cells grow more quickly.
Skip to content